NEWS
January 2025: Caranx Medical announces FDA submission of TAVIPILOT Soft:
the world first AI Software for real-time intra-operative guidance of transcatheter heart valve implantation.
Exciting progress at Caranx Medical!
This early October 2024, we’re conducting our Human Factors Engineering validation study in Chicago, followed by New York next week. We’re excited to test the usability of our TAVIPILOT® system with top interventional cardiologists and cardiac surgeons from leading structural heart hospitals in these regions.
This is the final step before our FDA submission for TAVIPILOT by the end of 2024 – a huge milestone for Caranx Medical on our journey to revolutionize TAVI procedures!
Stay tuned for more updates as we approach this pivotal moment!
Nice, France, April 16 th 2024 – Caranx Medical, announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal.
The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team.
“This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients’ lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx.
“This major medical first lies not only in the technical achievement of Caranx Medical’s engineers, but also in the impact that this technology will have on interventional cardiology practice. By simplifying and standardizing a complex procedure, the robot we have developed opens up new
possibilities for improving the performance and safety of TAVI procedures” says Dr. Eric Sejor, co-founder and CMO of Caranx.